Healthcare >> CEO Interviews >> May 8, 2002

Michael Hart – Allos Therapeutics Inc (alth)

MICHAEL E. HART is President and Chief Executive Officer of Allos Therapeutics, inc. He joined the company in 1999 and was promoted to President and Chief Executive Officer in December 2001 and to the Board of Directors in April 2002. Prior to his promotion, he was Chief Financial Officer and Senior Vice President of Operations. From 1998 to 1999, Mr. Hart served as Chairman of the Management Committee of NeXstar Pharmaceuticals, Inc., and led the sale of the company to Gilead Sciences in July 1999. From 1990 to 1998, Mr. Hart served as Vice President, Chief Financial Officer of NeXstar Pharmaceuticals Inc. and its predecessor Vestar, Inc. During his tenure, Mr. Hart was instrumental in building an international organization that supported $120 million in product revenues in over 30 countries around the world. During this period he also helped successfully guide NeXstar through two company acquisitions and several product approvals. Between 1976-1990, Mr. Hart held various financial positions with several high technology companies in the Silicon Valley. Mr. Hart received his MBA from California State University, Fresno, and his undergraduate degrees in Business Economics and Geography from the University of California, Santa Barbara. Profile
TWST: Can we start out with a quick update on the company? What's

gone on over the last year or so at Allos Therapeutics that

investors should focus on?

Mr. Hart: Our lead drug is RSR13, a